We evaluated prospectively the incidence and risk factors of the metabolic syndrome (MS) and its components in 170 adult patients (mean age at evaluation: 24.8 ± 5.4 years) who received an hematopoietic stem cell transplantation for childhood ALL, n = 119, or AML, n = 51. TBI was carried out in 124 cases; a busulfan-based conditioning was done in 30 patients. Twenty-nine patients developed a MS (17.1%, 95% confidence intervals: 11.7-23.6). The cumulative incidence was 13.4% at 25 years of age and 35.5% at 35 years of age. A higher body mass index (BMI) before transplantation and a growth hormone deficiency were associated with increased MS risk (P = 0.002 and 0.01, respectively). MS risk was similar for patients who received TBI or busulfan-based conditioning. The TBI use increased the hyperglycemia risk (odds ratio (OR): 4.7, P = 0.02). Women were at the risk of developing increased waist circumference (OR: 7.18, P = 0.003) and low levels of high-density lipoprotein cholesterol (OR: 2.72, P = 0.007). The steroid dose was not a risk factor. The MS occurs frequently among transplanted survivors of childhood leukemia. Its incidence increases with age. Both intrinsic (BMI, gender) and extrinsic factors (TBI, alkylating agents) contribute to its etiopathogenesis.
INTRODUCTION
With the improvement in childhood leukemia cure rate, the health status of survivors has become an important concern. [1] [2] [3] Many studies have focused on the increased cardiovascular risk in this population as it represents an important cause of morbidity and mortality. 4, 5 In a previous study, the Leucémie de l'Enfant et de l'Adolescent (LEA) study group showed that metabolic syndrome (MS), a well-known cardiovascular risk factor, 6, 7 was frequent among young adult survivors of childhood acute leukemia (AL). 8 The prevalence of MS was particularly high (15%) in patients who received hematopoietic stem cell transplantation (HSCT) despite their young age (mean age: 21.2 years). A higher risk for transplanted patients was confirmed by several other studies. [9] [10] [11] [12] [13] Some authors have shown an increase in MS prevalence in patients who underwent TBI; 9 our previous study was consistent with this hypothesis. However, the mechanism that underlies the pathophysiology of MS after HSCT is still poorly understood; most studies in this field have heterogeneous or small cohorts, making it difficult to draw definitive conclusions about prevalence or risk factors of MS in transplanted patients. 9, 10, [12] [13] [14] In this study, we aimed to describe the prevalence and cumulative incidence over time of MS and its components in a relatively large prospective cohort of adults surviving childhood AL who received an HSCT and to define risk factors for this condition.
PATIENTS AND METHODS Patients
The study was based on a cohort of young adults surviving childhood leukemia after HSCT, and who were included in the LEA program between 2007 and 2012 in 11 French cancer centers. This program was implemented in 2003 to prospectively evaluate the long-term health status, quality of life and socioeconomic status of childhood leukemia survivors who were enrolled in the treatment from 1980 to the present. Details of the entire program have been previously described. 15, 16 Since 2007, the assessment of MS was systematically proposed to all adults with a new LEA health status evaluation. The eligibility criteria were the following: (1) the provision of written informed consent for study participation in the LEA study, (2) age 418 years at the last LEA evaluation, (3) having received an HSCT after a myeloablative conditioning regimen. Data were collected during specific medical visits at predefined dates that occurred initially every 2 years and, afterward, every 4 years once a 10-year post-HSCT follow-up duration was achieved.
All patients (or their parents) provided written informed consent for participation. The study was approved by the French National Programme for Clinical Research and the National Cancer Institute and by the local institutional review boards.
Definition of MS and data collection MS was defined in accordance with the National Cholesterol Education Program Adult Treatment Panel III guidelines revised in 2005. 17 Patients were diagnosed with MS when they met at least three of the following criteria: (1) increased waist circumference (⩾102 cm in men, ⩾ 88 cm in women), (2) elevated blood pressure (systolic blood pressure ⩾ 130 mm Hg and/or diastolic blood pressure ⩾ 85 mm Hg) or on treatment for hypertension, (3) reduced high-density lipoprotein (HDL)-cholesterol (o40 mg/dL (1.03 mmol/L) in men, o 50 mg/dL (1.3 mmol/L) in women), (4) elevated fasting glucose (⩾1 g/L (5.5 mmol/L) or on drug treatment for elevated glucose) and (5) elevated triglycerides (⩾150 mg/dL (1.7 mmol/L)) or on drug treatment for elevated triglycerides. The body mass index (BMI) at transplantation was expressed as s.d., using French pediatric references.
Data on disease type, treatment, chemotherapy protocol and HSCT characteristics were extracted from the LEA database. The preparative regimen depended on the protocols in use at the time of transplantation, the underlying disease and its status and history of previous central nervous system irradiation. The prevention of GvHD was based on cyclosporine administration, sometimes in combination with methotrexate and/or steroids, depending on donor type and the protocol used at the time of HSCT. The occurrence and severity of GvHD were reported according to previously described criteria. 18 For each patient, the cumulative dose of prednisone and dexamethasone received as part of conventional therapy (that is, before HSCT) and during the posttransplantation period was collected. The total steroid dose, expressed in equivalents of prednisone, was calculated using the following formula: total steroid dose (mg/m 2 ) = (total prednisone dose (mg)+(total dexamethasone dose (mg) × 6.67))/body area (m 2 ). Three other late endocrine complications were also evaluated to determine a potential link with MS and include: growth hormone deficiency (GHD), hypogonadism and hypothyroidism. GH evaluation was done only for patients with decreased growth velocity whereas gonadal and thyroid function were systematically analyzed for all patients. GHD was detected by measuring plasma levels of insulin-like growth factor I and GH peak response to at least two stimulation tests. Hypogonadism was defined by low testosterone (males) or oestradiol (females) serum levels and classified as hyper-or hypogonadotrophic according to luteinizing hormone and follicle-stimulating hormone values. A diagnosis of subclinical hypothyroidism was made if the level of thyroid-stimulating hormone was high and the T4 level was normal, whereas overt hypothyroidism was diagnosed in patients with low T4 and high thyroidstimulating hormone levels.
Statistical analyses
Statistical analysis was conducted using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) and Intercooled Stata 9.0 for Windows. χ 2 -test and Fischer's exact tests were used to compare qualitative variables. Quantitative variables were compared using the Student's t-test or the Mann-Whitney test. The rates of prevalence of MS and its components are displayed with their 95% confidence intervals (CI).
Cumulative incidences of MS and each of its components over time were estimated using the Kaplan-Meier method, displayed with their 95% CI and compared with the log-rank test.
Multivariate logistic regression analyses were used to construct models of association between the occurrence of MS or its components and the potential risk factors. Explanatory variables included in the multivariate model were those we found significant in at least one univariate analyses (P ⩽ 0.05). Odds ratios (OR) were estimated with their 95% CI and the significance threshold was set as Po 0.05. Hazard ratios and their 95% CI were estimated with Cox proportional hazard models.
RESULTS
Comparison between eligible included and eligible non-included patients From among 228 eligible patients, 170 (74.6%) were included in this study ( Figure 1 ). No significant differences were found between the included patients and eligible patients who were not included because the data about MS were lacking (Supplementary Table 1 Metabolic syndrome in childhood leukemia survivors C Oudin et al
Patient characteristics
Of the 170 patients included, 45.9% were women and 70% had a diagnosis of ALL. The mean post-HSCT follow-up duration was 14.5 years (±6.1). The mean age at the last MS evaluation was 24.8 (±5.4) years. Patients were treated in accordance with current protocol at the time of leukemia diagnosis, depending on AL type (AML or ALL; that is, FRench group for childhood ALL (FRALLE), European Organisation for Research and Treatment of Cancer (EORTC), Leucémie Aiguë Myéloblastique Enfant (LAME) or ELAM). [19] [20] [21] [22] [23] Overall, 16 patients underwent central nervous system irradiation.
An allogeneic HSCT was carried out in 124 cases (72.9%), 46 patients (27.1%) received an autologous HSCT. TBI was used as a part of conditioning in 124 patients (72.9%). TBI was fractionated in all except two children and administered over 3 days with 2 Gy twice daily and a total dose of 12 Gy. Thirty patients (17.6%) underwent myeloablative conditioning with busulfancyclophosphamide. For patients who received an allogeneic HSCT, the donor type was a matched related donor in the majority of cases (n = 82 (66.1%)). The occurrence of acute GvHD (grade ⩾ 2) and extensive chronic GvHD were 22.9 and 8.2%, respectively. After HSCT, the mean steroid dose the patients received was 1488.6 mg/ m 2 . Salient patient characteristics are summarized in Table 1 .
Prevalence and cumulative incidence of MS and its components
The mean number of MS evaluations per patient was 1.38. Overall, MS was found in 29 (17.1%) patients (Table 2) . Low HDL cholesterol, high triglycerides and an elevated blood pressure were the most frequent pathologic components in this cohort (in 36.4, 29.6 and 30% of cases, respectively). Elevated fasting glucose was noted in 17.2% of cases, elevated waist circumference was observed in 15.1%. Of note, 33.5% had at least two pathologic components of the five. Two combinations of pathological variables accounted for most of MS cases: the association 'elevated triglycerides+low HDL cholesterol+hypertension' was found in 14 patients out of the 29 patients who have a MS (48.3%), and the association high triglycerides+low HDL cholesterol +elevated waist circumference in nine (29.3%).
Cumulative incidence curves of MS and each of its components are shown in Figure 2 and Supplementary Figure, respectively. Of note, curves represent incidences starting from age 18 (MS before this age was not documented). At 25 years of age, the cumulative incidence of MS was 13.4% (95% CI: 3.0-10.6) and reached 26.4% (95% CI: 17.6-38.3) at 30 years.
Risk factors for MS and its components
Multivariate logistic regression analyses were used to construct models of association between the occurrence of MS and its components (as the dependent variables) and potential risk factors (as the explanatory variables). The following explanatory variables were included, as they were found to be significant (P ⩽ 0.05) in the univariate analyses for the occurrence of MS or at least one of its components (Table 3) : gender, BMI at time of HSCT, type of transplantation (allogeneic versus autologous), conditioning regimen with or without TBI, follow-up duration (from the HSCT) and total dose of steroids post-HSCT. Leukemia type (ALL or AML), age at transplantation, central nervous system irradiation and acute or chronic GvHD showed significant impact neither on MS nor its components. Abbreviations: BMI = body mass index; Bu-cy = busulfan-cyclophosphamide; CNS = central nervous system; HSCT = hematopoietic stem cell transplantation; MS = metabolic syndrome. Abbreviations: CI = confidence interval; HDL = high-density lipoprotein.
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The only factor that was found to be significantly associated with MS was the BMI at the time of transplantation, which was higher for patients who developed MS in adulthood (OR: 1.57 (95% CI: 1.18-2.09) for each additional z-score unit, P = 0.002: Table 4 ). We found no impact of gender, type of transplantation, conditioning regimen, follow-up duration and total dose of steroids post-HSCT on MS occurrence. Similar results were found when using the Cox model with the same covariates (data not shown).
Multivariate logistic regression analyses were also used to describe risk factors associated with MS components (Table 4) . A higher BMI at transplantation was associated with increased risk of elevated glucose levels (OR: 1.5, 95% CI: 1.1-2.04), HDL cholesterol reduction (OR: 1.29, 95% CI: 1.01-1.65) and elevated blood pressure (OR: 1.4, 95% CI: 1.09-1.82).
Compared with men, women had a significantly higher risk of developing larger waist circumference (OR: 7.18, 95% CI: 1.91-26.96, P = 0.003) and low HDL cholesterol (OR: 2.72, 95% CI: 1.32-5.60, P = 0.007).
The risk of elevated fasting glucose was higher for patients who received TBI (OR: 4.7, 95% CI: 1.24-17.85) and for whom the follow-up was longer (OR: 1.13, 95% CI: 1.03-1.23).
Association of other endocrine late complication A significant association between MS and GHD was found: among 28 patients who had a GHD, 10 (35.7%) were found to have MS, whereas MS was present in only 3 (8.3%) of the 36 patients who had no GHD (P = 0.011). Of note, 26/28 patients who suffered from GHD received TBI during the conditioning. We did not observe any significant correlation between MS occurrence and hypogonadism or hypothyroidism (supplementary table 2).
DISCUSSION
We attempted to precisely describe the incidence and risk factors of MS in a cohort of adult patients who received an HSCT in childhood for the treatment of AL. This question is of particular interest because HSCT patients have been shown to be at high risk of developing cardiovascular events. [24] [25] [26] MS is a well-known risk factor for cardiovascular events, 6, 7 and early detection could lead to the institution of appropriate therapeutics to prevent the risk of such events.
We showed a high incidence of MS among our patients (13.4% at 25 years of age). This incidence appears to be very high when compared with that in the French general population: in a large French cohort, MS prevalence was 4% and 5.6%, respectively, for women and men between 30 and 39 years of age. 27 The high prevalence found in the present study (17.1%) is consistent with our previous study in this field, which showed a prevalence of 15% among 60 transplanted patients. 8 Several studies have also shown an increased risk of developing MS in the HSCT population, but most of them are limited due to the small study sample, the retrospective nature of the study, or the heterogeneity of the population studied. [9] [10] [11] [12] 14, 28 This could explain why the prevalence of MS reported previously is so variable, ranging from 7.5% to 49%. [9] [10] [11] [12] [13] In this study, we confirm that HSCT patients can develop this syndrome a long time after the HSCT: the cumulative incidence of MS and each of its components is increasing progressively as patient age increases. These results strongly support the need for a prolonged follow-up of MS and cardiovascular events in HSCT patients.
We previously reported an important impact of TBI-containing conditioning regimens on the occurrence of MS (OR: 3.9 (95%CI: 1.1-13.3)). 8 In the present study, the risk for patients with TBI appears similar to the risk for those transplanted after a busulfancontaining myeloablative conditioning regimen (that is, busulfancyclophosphamide in the majority of them). This is consistent with some other studies 10, 11, 24 and suggests that high-dose alkylating agents could also promote the occurrence of MS. The endothelial damage caused by alkylating agents or TBI exposure 29 has been frequently reported, [30] [31] [32] and could promote the development of MS. [33] [34] [35] Of the different MS components, the only significant impact noted was that of TBI on hyperglycemia (OR: 4.7, 95%CI: 1.24-17.85, P = 0.02). When insulin resistance is considered one of the main mechanisms involved in MS development, 36 it can be hypothesized that TBI exposure could promote secondary development of MS by this mechanism. Two major hypotheses have been proposed to explain the role of TBI on hyperglycemia: pancreatic irradiation could impair the β-cells ability to produce insulin and cause hyperglycemia by this way. 37, 38 Other authors suggested that hyperglycemia is a component of the insulin resistance state often observed in childhood leukemia survivors after TBI. 39, 40 In the present study, we found a significant impact of a higher BMI at the time of transplantation, not only on the development of the MS but also on HDL cholesterol, hyperglycemia and waist circumference. The impact of abdominal obesity on MS has been reported in many studies in the general population, 41, 42 but such results have not been previously reported in patients who received an HSCT for childhood leukemia.
Modifications of adipose tissue metabolism are now recognized as a fundamental mechanism for the development of MS in the general population: 43 a defect in the adipose tissue expansion ability (often found in obese people) induces ectopic lipid repartition, which can cause insulin resistance and MS. Here, we can hypothesize that patients with higher pre-transplantation BMI are predisposed to the development of post-transplantation MS and additional factors such as TBI or alkylating agent exposure could worsen adipose tissue abnormalities and contribute to the development of MS. 44, 45 However, this hypothesis remains to be confirmed by further studies.
In the present study, women were found to be at the risk of developing larger waist circumference, as compared with men (OR: 7.18, P = 0.003). This higher risk is all the more remarkable because, in the general population, men are usually more prone to abdominal obesity than women. Such a sensitivity has been shown previously: [46] [47] [48] women who received cranial irradiation were more likely to develop obesity. Women from our cohort were also more likely to have lower HDL cholesterol. Taken together, these results suggest a higher sensitivity of female patients to TBI or alkylating agents.
We did not find any impact of the post-transplantation steroid dose or GvHD on MS or any of its components. Some previous Metabolic syndrome in childhood leukemia survivors C Oudin et al studies found conflicting results on this point: some authors reported that steroids could increase the risk of MS, 10 whereas others reported that steroids have no impact. 12, 48, 49 The results concerning the role of GvHD are also controversial 12, 13, 50 and are based on retrospective analyses or small cohorts. Finally, the MS incidence was not higher in allo-HSCT compared with that in the auto-HSCT group.
We report a strong association between MS and a GHD: 35.7% of patients with GHD also had MS (P = 0.011). Several studies support the association between GHD and a MS; 50-53 these late complications have both been linked with cranial irradiation, probably due to its toxicity for the pituitary gland. [50] [51] [52] Therefore, GHD is probably one of the mechanisms involved in metabolic dysfunction.
The present study takes advantage of the prospective nature of the cohort and of its homogeneity, both in terms of age at diagnosis and evaluation, disease type and treatment modalities. To our knowledge, this is the largest prospective study ever described in this field among patients transplanted for childhood AL. However, the smaller number of included patients could contribute to obscure risk factors that have been proposed in other studies (steroids, GvHD…). 50 Despite a long follow-up duration (mean: 14.5 years), the rather young age of our patients could lead to an undervaluation of MS incidence. We only performed a mean of 1.38 MS evaluation per patient. It would be interesting to analyze higher number of evaluations, so as not to undervalue the MS incidence. The precise relation between the MS and cardiovascular events was not assessed in this study: we report only three cardiovascular events, making it impossible to characterize a possible link with the MS. We did not investigate the insulin blood level, which may have been of interest. However, we focused our analyses on clinical data and simple biological analyses, which could easily be done in routine medical visits.
CONCLUSION
The mechanisms underlying the MS development are multifactorial. Among intrinsic factors, pre-transplantation BMI and female gender, seem to have a strong impact. Among extrinsic factors, TBI and alkylating agents may have an important role, but their exact responsibility is difficult to identify in the overall context of HSCT.
If the precise impact of each factor is to be ascertained, clinicians have to keep in mind that patients who received an HSCT for childhood leukemia are at high risk of developing MS. Among this population, long-term medical follow-up and lifestyle interventions should systematically be proposed to prevent premature cardiovascular morbidity and mortality. So, we recommend for LEA transplanted patients a regular monitoring of the MS components, once every 4 year. If one or more component appears, patients should be addressed to the endocrinology consultation for appropriate care.
